Glycopeptide antibiotics have been the subject of intense investigation in recent years along with the appearance in hospitals of Staphylococcus aureus and Staphylococcus epidermidis that are resistant to methicillin treatment. Besides vancomycin, the new glycopeptide teicoplanin^(Targocid) has recently been introduced in therapeutic use in some countries. Teicoplanin (I) (Fig. 1) consists of five major closely related factors (A2/1~5) differing in the iV-acyl chain linked with /3-D-glucosamine at position C-56. It also contains one a-D-mannose and one Af-acetyl-^-D-glucosamine at C-42 and C-34 positions, respectively. All three sugars can be removed by acidic hydrolysis under selected conditions obtaining the aglycone (II) (Fig. 1) . 2) From the first observation by Chatterjee and Perkins3) that the glycopeptide vancomycin formed a stoichiometric 1 : 1 complex with cell-wall precursors terminating with the peptide D-alanyl-D-alanine, much evidence has been obtained on the mechanism of action of glycopeptide antibiotics.4>5) The role of the terminus amino group of glycopeptide antibiotics in the binding to bacterial cell-wall model iV-acetyl-D-alanyl-D-alanine (Ac-D-Ala-D-Ala) has been studied. 6 ) Data indicate that iV-terminus favors the initial Coulomb complex with the carboxylate ion of the peptide but is not essential for the binding.6~8) Continuing8) our study on teicoplanins concerning the importance of the iV-terminus group for antibacterial activity, we synthetized a series of thioureas III and isothiouronium salts IV of I and II (Scheme 1). In this paper, for conciseness, only the derivatives of II are reported.
The binding constants (KA, m"1) of a few derivatives with Ac-D-Ala-D-Ala were measured by UV differential spectroscopy.
Chemistry
Nine thiourea derivatives of II (1~9 , Table 1 ) were prepared according to Scheme 1 utilizing commercially available isothiocyanates as starting material in a CH3CN -H2Omixture. The synthesis of unsubstituted thiourea III (R4=H, 2) failed when potassium or ammoniumthiocyanate in different reaction conditions were used. Then the two step synthesis, described by Douglass and Dains,9) was followed. In the first step substrate II reacts with benzoyl thiocyanate (Method A) to obtain structure III (R4=COC6H5,1). The second step is the alkaline hydrolysis of the benzoyl group. Because the hydrolysis conditions of the Douglass method (10% NaOHboiling) are too drastic, and epimerization at the C-3 position mayoccur, a use gentle or weak hydrolysis with K2CO3 in acetone at room temperature was used (Method B). The isothiouronium salts IV (Scheme 1), listed in Table 2 were obtained by £-alkylation of thioureas III with CH3I (10 and 12~17) or with C2H5Br (ll). As expected, isothiouronium salts IV are more soluble in water than the corresponding thioureas III, but their solubility does not significantly differ from parent antibiotic II. Compoundsof structure IV are not stable as free bases in water and undergo a hydrolysis resulting in the formation of mercaptane. Whena chromatographic purification was necessary, 1 n HC1was added (1 %) to the eluting solvent to maintain the correct acidity of the mobile phase. Following this procedure the compounds were recovered as hydrochlorides. The acid-base titration of II in methyl cellosolve (MCS) -H2O (4 : 1) shows two ionizable functions, with the apparent pK values of 4.8 and 6.9 which are attributed to the terminal carboxyl and amino groups, respectively, which give rise to a zwitterion. Thioureas III exhibit only one potentiometric detectable function attributable to the terminal carboxyl group (Table 1) whereas isothiouronium salts show an acidic and a basic function ( Table 2 ). The pKvalue of the isothiouronium group is affected by the electronic character of substituent R4 (IV, Scheme 1). While alkyl groups give about pK 7 (Table 2) , an electron withdrawing group decreases it to 3.5 (16).
The reactions and the purity of the compoundswere carefully monitored by reverse phase HPLC. In the HPLCmobile phase conditions (pH 4.7 see Experimental section) isothiouronium derivatives IV were eluted before the corresponding thioureas III even though IV had the lipophilic contribution of the additional alkyl R4 (Scheme 1). Compounds 16 and 17 have a low pKand remain non-ionized in HPLCbuffer and hence show longer retention times (tR) than the corresponding thioureas 8 and 9 as expected. The IR spectra give mainly two pieces of information ; one is general and is concerned with the maintaining of the peptide or glycopeptide structure in these compounds. The other is specific and is concerned with the ionization state of the terminal carboxyl group (v C=Oof COOHgives a shoulder at 1730 cm"1).
1H NMRspectral assignments (Table 3) confirm the overall structural features concerning the peptide core and the moiety chemically introduced. The chemical shift of the 15-H signal (aproton of amino acid 1) is sensitive to the nature of such a moiety. It undergoes a downfield shift with respect to the same 15-H signal in the parent compound. Whenit is not overlapped by other peaks, as generally happens in the case of the isothiouronium salts, this signal is found in the range 5.6~6.2 ppm.
Results and Discussion
The role of the terminal amino group in glycopeptide antibiotics seems to consist mainly of favoring the binding with peptides terminating in acyl-D-alanyl-D-alanine.5)
Moreover, the ionization of the iV-terminus group affects the antibiotic water solubility.
The reason for the synthesis of derivatives III and IV of aglycone described here was to study 
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a MICwas determined using the 2-fold dilution method in microtiter system. The media used were:
Iso-Sensitest broth (Oxoid) for Staphylococci, S. faecalis and Gram-negative bacteria ; Todd-Hewitt broth (Difco) for Streptococci. The final inoculum was about 104cfu/ml. MICwas read as the lowest concentration which showed no visible growth after 18~24 hours incubation at 37°C. nd: Not determined.
how the degree of ionization of the JV-teiminus affects the binding with Ac-D-Ala-D-Ala and antibacterial activity. The binding strength of four compoundshave been measured by UVspectroscopy and compared with those of the aglycone and of the 15-deamino compound(TDW).8) The binding constants (KA) with the bacterial cell-wall model are in accordance with our expectations. In fact, the isothiouronium compounds (10 and 12) that possess a terminal protonable group (6) (7) (8) show KAof the same magnitude of the aglycone while the thiourea compounds(2 and 6) have a lower KA9com-parable to that of TDW. The in vitro antibacterial activities of thiourea and isothiouronium derivatives (III and IV) are reported in Tables 5 and 6 in comparison with that of parent antibiotic II. Also reported is the activity of TDWwhich lacks the amino terminus and should represent the least active compound. The comparison of the thiourea derivative with the corresponding isothiouronium compoundactivities shows differences too small to suggest a correlation between degree of ionization of the 15-terminal group and antibacterial activity. A 10-fold difference in the binding constant, measured by UVspectroscopy, cannot predict a significant variation in the in vitro activity probably because the UVassay does not consider the diffusion capability of compoundsin cell-walls. Corresponding teicoplanin (I) derivatives were synthesized with the same procedure utilized for preparing aglycone derivatives (1~4, and 13 and 14 see Experimental section). For these compounds as well the in vitro antibacterial activity was comparable to that of the parent antibiotic. 
Experimental
Evaporation of solvents was carried out, after adding BuOHto prevent foaming with a rotary evaporator at 45°C under vacuum. If not otherwise stated, the intermediates and the final products were washed with Et2O and dried at 40°C under vacuum.
Column chromatography was performed using silanized Silica gel 60 (0.06~0.2 mm)(Merck). HPLCwas applied to monitor reactions, chromatographic fractions, and purity of the compounds using a Hewlett-Packard 1090L chromatograph equipped with a UVdetector at 254 nm and ODS-Hypersil C-18 (100mm, 5 jum) column. Injection volume, 10 [A; flow rate, 1 ml/minute; mobile phases : (A) 0.02 aq NaH2PO4(pH 4.7); (B) CH3CN; linear step-gradient as follows: All compounds were analyzed for C, H, N, and S on samples previously dried at 140°C under N2 atmosphere. Weight loss was determined by TGAat 140°C; inorganic residue was determined after heating the samples at 900°C in O2atmosphere. The analytical results were in accordance with the theoretical values.
Fast atom bombardment mass spectra (FAB-MS)positive ion spectra were obtained on a Kratos MS-50 instrument fitted with a standard FABsource and a high-field magnet; the sample (lO^mol) was dispersed in a few [A of 2-thioglycerol -diglycerol (1 : 1) matrix and bombarded with a 6^9-Kevbeamof Xe atoms.
The p^mcs values were determined potentiometrically in MCS-H2O(4 : 1) solution. An excess of 0.01 n HC1in the same solvent mixture was added and the resulting solution was titrated with 0.01 n NaOH in the same solvent mixture.
The IR spectra were obtained in a Nujol mull with a Perkin-Elmer 850 instrument. The XHNMR spectra were obtained with a Bruker instrument AM250 equipped with an Aspect 3000 console at 250 MHz. The spectra were recorded at 40°C in DMSO-d6solution (internal standard TMS, d 0.00). The binding constants were measured with Ac-D-Ala-D-Ala by UVdifferential spectroscopy as previously described.8)
MICwas determined using the 2-fold dilution method in microtiter system. The media used were : Todd-Hewitt broth (Difco) for Streptococci and Iso-Sensitest broth (Oxoid) for Staphylococci, Streptococcus faecalis and Gram-negative bacteria. The final inoculum was about 104 cfu/ml. MIC AUG. 1989 was read as the lowest concentration which showed no visible growth after 18~24 hours incubation at37°C.
Thioureas of the Aglycone Method A N15-(Benzoylamino)thioxomethyl (1): Aglycone (II) (4.8 g, 4 mmol) and Na2CO3 (0.53 g, 5 mmol) were dissolved in DMF(150 ml) then benzoyl isothiocyanate (0.6 ml, 4.4 mmol) was added and the mixture stirred at room temperature for 5 hours. The mixture was diluted with 1.5 liters of water and the pH adjusted to 3, and the product was extracted with 800 ml of a mixture of BuOHEtOAc(7 : 3). The organic solvent, washed with water (150 ml), was concentrated to a final volume of about 60 ml, and by adding Et2O (300 ml) a solid separated which was collected. This crude material (5.8 g) containing a less lipophilic compound was purified by chromatography on a column packed with 500 g of silanized silica gel developed with a linear gradient from 15 to 40% of CH3CN in water. By working out the appropriate fractions, 2.5 g of compound1 were obtained.
Method B N15-(Aminothioxomethyl) (2): A solution of 1 (2.5 g, 1.8 mmol), K2CO3 (2g, 14.4mmol) in 100ml of Me2CO-H2O (1 :1) was stirred 2 hours at room temperature. Acetone was removed under vacuum and the aqueous solution, adjusted to pH 3, was extracted with BuOH(100 ml). The organic layer, washed with water (30 ml) was evaporated to dryness. The residue was triturated with Et2O, filtered and washed with Et2O, yielding 1.8 g of the title compound. MethodC N15-(Phenylmethyl)aminothioxomethyl (7): A solution of II (5g, 4.1 mmol) in 300ml of CH3CN-H2O (1 : 1) containing benzyl isothiocyanate (0.6 ml, 4.6 mmol) was stirred at 40°C for 5 hours mantaining the pH at 7.5 by adding 1 n NaOH.If after this time some starting material was still present (HPLCassay) additional isothiocyanate was added. The organic solvent was evaporated under vacuum, the water, brought to pH 3, was extracted with 300ml of a mixture of BuOH-EtOAc (3 : 1) and the organic layer washed with water. The residue obtained after solvent evaporation was triturated with Et2O filtered and dried under vacuum, yielding 5 g of a crude material, which was purified by column chromatography on silanized silica gel eluting with a linear gradient CH3CN-H2Ofrom 10 to 40%of CH3CN.By working out the appropriate fractions 2.5 g of title compound were obtained. MethodD N15-(Ethoxycarbonylamino)thioxomethyl (5): A solution of II (2 g, 1.66 mmol), in 100ml of CH3CNand 20 ml of H2O, was treated with ethoxycarbonyl isothiocyanate (40 ml) and the mixture stirred at roomtemperature overnight. The solvents were evaporated under vacuumat 45°C. The residue was then treated with Me2CO,filtered, washed with Et2O and dried under vacuum, yielding 2 g of 90% pure (HPLC) title compound.
Isothiouronium Salts of the Aglycone Method E N15-(Cyclohexylimino)(methylthio)methyl (14) : A solution of compound 6 (2 g, 1.58 mmol) in 40mlofMeOHwas stirred at room temperature while a total of 1 ml (16mmol) of CH3I was added over 48 hours. The solvent was concentrated to a small volume and by adding Et2O (100 ml) a precipitate formed which was filtered and dried under vacuum. Yield 1.8 g of title compound. 2 mmol) and EtBr (0.4 ml, 5 mmol) in 30 ml of CH3CNand 5 ml of H2Owas stirred at 40°C while additional EtBr (0.4 ml) was added over 24 hours. The reaction, cooled at room temperature, was diluted with 100 ml water and then loaded on the top of a chromatographic column containing 150 g of silanized silica gel. The product was eluted with a linear gradient from 10 to 30% of CH3CNin water containing 0.1 % 1 n HC1. The fractions containing pure product (>90% HPLC) were pooled, BuOH was added and the solvents were evaporated to dryness. The residue was tritured with H2Oand filtered. Yield 400 mgof title compound.
